Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors

Neuroscience

Volumn 99, Issue 1, 2000, Pages 17-23

  Barnes, C A ^a   Meltzer, J ^a   Houston, F ^a   Orr, G ^a   McGann, K ^a   Wenk, G L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

AChE inhibitors; Aging; long term potentiation; Spatial memory

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NICOTINIC RECEPTOR;

AGED; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPUS; LONG TERM CARE; LONG TERM POTENTIATION; MINIPUMP; NEOCORTEX; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SYNAPTIC TRANSMISSION; WORKING MEMORY;

ACETYLCHOLINESTERASE; AGE FACTORS; ANIMALS; CHOLINESTERASE INHIBITORS; EXCITATORY POSTSYNAPTIC POTENTIALS; GALANTAMINE; HIPPOCAMPUS; INDANS; MALE; MEMORY; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, INBRED F344; RECEPTORS, NICOTINIC;

EID: 0034718202     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00180-9     Document Type: Article

References (51)

1. Abdulla F.A., Bradbury E., Calaminici M.R., Lippiello P.M., Wonnacott S., Gray J.A., Sinden J.D. Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation. Psychopharmacology. 124:1996;323-331.
2. Albuquerque E.X., Pereira E.F., Alkondon M., Schrattenholz A., Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J. Recept. Signal Transduction Res. 17:1997;243-266.
3. Allen S.J., Dawbarn D., Wilcock G.K. Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer's disease. Brain Res. 454:1988;275-281.
4. Bach M.E., Barad M., Son H., Zhuo M., Lu Y.-F., Shih R., Mansuy I., Hawkins R.D., Kandel E.R. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. natn. Acad. Sci. USA. 96:1999;5280-5285.
5. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. comp. physiol. Psychol. 93:1979;74-104.
6. Barnes C.A., Jung M.W., McNaughton B.L., Korol D.K., Andreasson K., Worley P.F. LTP saturation and spatial learning disruption: effects of task variables and saturation levels. J. Neurosci. 14:1994;5793-5806.
7. Bigl V., Arendt T., Fischer S., Fischer S., Werner M., Arendt A. The cholinergic system of aging. Gerontology. 33:1987;172-180.
8. Bliss T.V.P., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anesthetized rabbit following stimulus of perforant path. J. Physiol. 232:1973;331-356.
9. Cooper J.C., Gutbrod O., Witzemann V., Methfessel C. Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes. Eur. J. Pharmac. 309:1996;287-298.
10. Dal-Bianco P., Maly J., Wober C., Lind C., Koch G., Hufgard J., Marschall I., Mraz M., Deecke L. Galanthamine treatment in Alzheimer's disease. J. neural Transm. 33:1991;59-63.
11. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27:1990;457-464.
12. de Toledo-Morrell L., Geinisman Y., Morrell F. Age-dependent alterations in hippocampal synaptic plasticity: relation to memory disorders. Neurobiol. Aging. 9:1988;581-590.
13. Deupree D.L., Bradley J., Turner D.A. Age-related alterations in potentiation in CA1 region in F344 rats. Neurobiol. Aging. 14:1993;249-258.
14. Ellman G.L., Courtney K.D., Andres V. Jr, Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmac. 7:1961;88-95.
15. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J.A. A controlled trial of tacrine in Alzheimer's disease. J. Am. med. Ass. 268:1992;2523-2529.
16. Fulton B., Benfield P. Galanthamine. Drugs Aging. 9:1996;60-65.
17. Giacobini E. Cholinergic foundations of Alzheimer's disease therapy. J. Physiol., Paris. 92:1998;283-287.
18. Harvey A.L. The pharmacology of galanthamine and its analogues. Pharmac. Ther. 68:1995;113-128.
19. Hellstrom-Lindahl E., Moore H., Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholineserase inhibitors and nicotinic agonists. J. Neurochem. 74:2000;777-784.
20. Irwin R.L., Smith H.J. Cholinesterase inhibition by galanthamine and lycoramine. Biochem. Pharmac. 3:1960;147-148.
21. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur. J. Pharmac. 386:1999;7-13.
22. Malenka R.C., Nichol R.A. Long-term potentiation - a decade of progress? Science. 285:1999;1870-1874.
23. Mann D.M.A. Pathological correlates of dementia in Alzheimer's disease. Neurobiol. Aging. 15:1994;357-360.
24. Marchi M., Raiteri M. Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function. J. Neurochem. 67:1996;1974-1981.
25. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging, Alzheimer's disease and the cholinergic system of the basal forebrain. Neurology. 34:1984;741-745.
26. Moore C.I., Browning M.D., Rose G.M. Hippocampal plasticity induced by primed burst, but not long-term potentiation, stimulation is impaired in area CA1 of aged Fischer 344 rats. Hippocampus. 3:1993;57-66.
27. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscaranic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31:1992;103-111.
28. Olton D.S., Samuelson R.J. Remembrance of places passed: spatial memory in rats. J. exp. Psychol. 2:1976;1005-1008.
29. Pacheco G., Palacios-Esquivel R., Moss D.E. Cholinesterase inhibitors proposed for treating Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J. Pharmac. exp. Ther. 74:1995;767-770.
30. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Molec. Pharmac. 46:1994;523-530.
31. Pietila K., Lahde T., Attila M., Ahtee L. Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn-Schmiedeberg's Arch. Pharmac. 357:1998;176-182.
32. Proskurnina N.F., Yakovleva A.P. Alkaloids of Galanthus woronowi. II. Isolation of new alkaloid. J. gen. Chem. 22:1952;1899-1902.
33. Rinne J.O., Paljarvi L., Rinne K. Neuronal size and density in the nucleus basalis of Meynert in Alzheimer's disease. J. neuronal Sci. 79:1987;67-76.
34. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archs intern. Med. 158:1998;1021-1031.
35. Rogers S.L., Yamanishi Y., Yamatsu K. E-2020: the pharmacology of a piperidine cholinesterase inhibitor. Becker R., Giacobini E. Cholinergic Basis of Alzheimer Therapy. 1991;Birkhauser, Boston.
36. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Molec. Pharmac. 49:1996;1-6.
37. 3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J. Neurochem. 45:1985;427-433.
38. Shen J., Barnes C.A. Age-related decrease in cholinergic synaptic transmission in three hippocampal subfields. Neurobiol. Aging. 17:1996;439-451.
39. Shen J., Barnes C.A., Wenk G.L., McNaughton B.L. Differential effects of selective immunotoxic lesions of medial septal cholinergic cells on spatial working and reference memory. Behav. Neurosci. 110:1996;1181-1186.
40. Snape M.F., Misra A., Murray T.K., De Souza R.J., Williams J.L., Cross A.J., Green A.R. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology. 38:1999;181-193.
41. Sparks J.A., Pauly J.R. Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology. 141:1999;145-153.
42. Svensson A.-L., Nordberg A. Tacrine interacts with an allosteric activator site on α4β2 nAchRs in M10 cells. NeuroReport. 7:1996;2201-2205.
43. Sweeney J.E., Puttfachken P.S., Coyle J.T. Galantamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmac. Biochem. Behav. 34:1989;603-605.
44. Thomsen T., Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 46:1990;1553-1558.
45. Thomsen T., Bickel U., Fischer J.P., Kewitz H. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia. 1:1990;46-51.
46. Vogels O.J.M., Broere C.A.J., Ter Laak H.J., ten Donkelaar H.J., Nieuwenhuys R., Schulte B.P. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol. Aging. 11:1990;3-13.
47. Wang T., Tang X.C. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur. J. Pharmac. 349:1998;137-142.
48. Watkins P.B., Zimmerman H.J., Knapp M.J. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J. Am. med. Ass. 271:1994;992-998.
49. Wenk G.L. The nucleus basalis magnocellularis cholinergic system: 100 years of progress. Neurobiol. Learn. Mem. 67:1997;85-95.
50. Wilcock G.K., Scott M., Pearsall T., Neubauer K., Boyle M., Razay G. Galanthamine and the treatment of Alzheimer's disease. Int. J. geriatr. Psychiat. 8:1993;781-782.
51. Wilkinson D. Clinical experience with Donepezil (Aricept) in the UK. J. neural Transm. 54:1998;311-315.